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ABSTRACT
Nicotine dependence is the leading cause of death in the United States. However, research on high rates of nicotine use
in mental illness has primarily explained this co-morbidity as reflecting nicotine’s therapeutic benefits, especially for
cognitive symptoms, equating smokingwith ‘self-medication’.We used a leading neurodevelopmental model of mental
illness in rats to prospectively test the alternative possibility that nicotine dependence pervades mental illness because
nicotine is simply more addictive in mentally ill brains that involve developmental hippocampal dysfunction. Neonatal
ventral hippocampal lesions (NVHL) have previously been demonstrated to produce post-adolescent-onset, pharma-
cological, neurobiological and cognitive-deficit features of schizophrenia. Here, we show that NVHLs increase adult
nicotine self-administration, potentiating acquisition-intake, total nicotine consumed and drug seeking. Behavioral
sensitization to nicotine in adolescence prior to self-administration is not accentuated by NVHLs in contrast to
increased nicotine self-administration and behavioral sensitization documented in adult NVHL rats, suggesting
periadolescent neurodevelopmental onset of nicotine addiction vulnerability in the NVHLmodel. Delivering a nicotine
regimen approximating the exposure used in the sensitization and self-administration experiments (i.e. as a treatment)
to adult rats did not specifically reverse NVHL-induced cortical-hippocampal-dependent cognitive deficits and actually
worsened cognitive efficiency after nicotine treatment stopped, generating deficits that resemble those due to NVHLs.
These findings represent the first prospective evidence demonstrating a causal link between disease processes in
schizophrenia and nicotine addiction. Developmental cortical-temporal limbic dysfunction in mental illness may thus
amplify nicotine’s reinforcing effects and addiction risk and severity, evenwhile producing cognitive deficits that are not
specifically or substantially reversible with nicotine.
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INTRODUCTION
With pathogenic effects spanning brain and cardiopul-
monary systems, nicotine dependence remains the single
largest cause of death in the United States (Mokdad et al.
2004). As general population rates have fallen below
25%, smoking has become more concentrated in the
mentally ill who now consume around half of all
cigarettes sold (Lasser et al. 2000; Grant et al. 2004).
Smoking rates exceeding 75% in schizophrenia popula-
tions are associated with decades cut from individual life
spans, lower psychiatric treatment compliance and
financial impoverishment as government assistance for
the mentally ill is channeled into tobacco industry profits
(Steinberg, Williams & Ziedonis 2004; Parks et al. 2006;
Prochaska, Hall & Bero 2008).
Psychiatric research on nicotine use in mental illness
has traditionally been guided by the hypothesis that this
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comorbidity reflects therapeutic effects of nicotine and/
or tobacco, so that smoking in mental illness is widely
accepted as synonymous with ‘self-medication’ (Dani
& Harris 2005; DeHay et al. 2012). Human data
encompassing genetic and histological analyses of nico-
tinic receptors and electrophysiological and cognitive
responses to nicotine have been suggested to reflect
schizophrenia-specific abnormalities that allow nicotine
to function as a cognitive enhancer in this illness (Leonard
et al. 2001; Dani & Harris 2005). Although this research
has imparted neuroscientific credence to a medicinal
value for nicotineuse in schizophrenia, recently emerging
data indicate that acute nicotine dosing has no cognitive
therapeutic benefits for schizophrenic compared to non-
schizophrenia smokers (Hahn 2013). Also, growing evi-
dence suggests that chronic nicotine exposure may
actually cause rather than treat cognitive and affective
symptoms (Reitz et al. 2007; Slotkin 2008; Counotte et al.
2011; McDermott et al. 2013).
Generally, the self-medication hypothesis has not
translated well into motivating clinicians or patients to
treat nicotine addiction (DeHay et al. 2012), nor does
it effectively explain why schizophrenia patients have
increased addictions to other drugs like cocaine and
alcohol, which are known for exacerbating rather than
improving psychotic and/or cognitive symptoms (Volkow
2009). Given this larger picture, an alternative hypothesis
becomesapparent: theconnectionbetweenschizophrenia
and nicotine dependence may reflect a more general, and
involuntary biological process where one brain disease
(i.e. schizophrenia) predisposes to and synergizes with
another (i.e. addiction) (Chambers, Krystal & Self 2001).
Directly testing this alternative hypothesis necessi-
tates pre-clinical approaches, not ethically possible in
human subjects, where addictive drugs can be prospec-
tively tested in well-controlled experiments using heuris-
tic, drug-naive animal models of mental illness. For this
purpose, we have applied the neonatal ventral hippo-
campal lesion (NVHL) model of schizophrenia. In this
model, the axon-sparing neurotoxin ibotenic acid is
delivered into the hippocampus of 7-day-old rats corre-
sponding to the second trimester human fetal brain devel-
opment when environmental and genetic risk factors are
implicated in seeding schizophrenia (Lipska, Jaskiw &
Weinberger 1993;Weinberger 1999). Similar to observa-
tions in humans with schizophrenia, NVHL rats have
hippocampal atrophy that is proportional to overall
syndrome severity (Chambers et al. 1996; Brambilla
et al. 2013), and many secondary neurobiological and
behavioral abnormalities involving prefrontal-cortical-
striatal anatomy and function (Tseng, Chambers & Lipska
2009). Developmentally, NVHLs produce post-adolescent
onset of ‘positive’ symptom-like behavioral abnormali-
ties that are reducible with antipsychotic medications,
superimposed on more insidiously presenting, earlier
onset, cognitive and ‘negative’ symptoms that do not
respond to anti-psychotics (Tseng et al. 2009).
Illustrative of a fundamental neurobiological connec-
tion between severe mental illness and addiction vulner-
ability, NVHLs also cause an involuntary amplification of
short- and long-term behavioral sensitization to cocaine
(Chambers & Taylor 2004), alcohol (Conroy, Rodd &
Chambers 2007) and nicotine (Berg & Chambers 2008),
corresponding to increased self-administration of cocaine
(Chambers & Self 2002) and alcohol (Berg, Czachowski &
Chambers 2011). The present study was designed to test
whether this addiction vulnerability generalizes to nico-
tine, and to capture first proof of a causative relationship
between early disruptions of hippocampal network devel-
opment and adult-age nicotine addiction vulnerability,
co-occurringwithcognitive impairments thatmayormay
not respond therapeutically to nicotine.
METHODS AND MATERIALS
Subjects and neonatal surgeries
Subjects were born in our facility from Sprague-Dawley
females arriving at 14–16 days gestation (Harlan, Indi-
anapolis, IN, USA). Post-natal day (PD)-5 litters were
culled tomales in preparation for surgeries on PD-7. Pups
weighing 16–19 g underwent surgeries performed under
hypothermic anesthesia. Briefly, as described elsewhere
(Lipska et al. 1993), stereotaxic-assisted Hamilton needle
placement into the ventral hippocampus bilaterally
(anterior-posterior –3.0 mm, medial-lateral ± 3.5 mm,
anddorsal-ventral −5.0 mm from bregma) was followed
by Ibotenic acid (3.0 μg; Sigma, St. Louis,MO, USA) deliv-
ery in 0.3 μl artificial cerebrospinal fluid (aCSF) to NVHL
rats, or aCSF only to Sham-operated rats. Pups were
returned to their awake mothers after 30 minutes of
recovery on a heating pad, and thereafter reared under
standard conditions until weaning on PD-21. At
weaning, NVHL and Sham rats were housed in pairs (like
lesion status) until adulthood (PD-56), when they were
individually housed. Surgical and experimental proce-
dures were conducted in accordance with the National
Institutes of Health Guide for the Care and Use of Labo-
ratory Animals and the Indiana University Institutional
Animal Care and Use Committee.
Nicotine preparation
Nicotine hydrogen tartrate salt (Sigma) was dissolved in
0.9% sterile saline to a stock solution dose of 0.5 mg/ml
[expressed in terms of the base of the salt (Matta et al.
2007)], adjusted to a pH 7.4. This solution was injected
subcutaneously (sc) for adolescent sensitization and in
the cognitive testing as pre-injections in volumes of 1 ml
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per kg of rat weight. For i.v. self-administration, doses
were prepared daily on a per rat weight basis from stock
solutions.
Adolescent behavioral sensitization to nicotine
During mid-adolescence (PD-34 to 44), rats destined for
adult nicotine self-administration were given 10 once
daily injections (sc) of nicotine (0.5 mg/kg) or saline
(1 ml/kg) during locomotor testing in 43 × 43 cm
plexiglass arenas (Med Associates, St. Albans, VT, USA),
equipped with 16 infrared beam arrays. Position, track,
distance, speed and non-ambulatory movements were
recorded over the 2-hour sessions. Rats were tested under
red light and had injections delivered at the beginning of
the second hour.
Adult intravenous cannulation and
nicotine self-administration
On PD-56, subjects entering self-administration under-
went jugular venous catheterization under sodium pen-
tobarbital anesthesia. As detailed elsewhere (Chambers
& Self 2002), Silastic tubing (Green Rubber, Woburn,
MA, USA) placed into the animal’s right vein coursed
subcutaneously over the shoulder to exit the back via
a 22-gauge cannula (Plastics One, Roanoke, VA, USA).
Catheters were flushed daily with 0.3 ml heparinized
saline (20 IU/ml) containing gentamicin sulfate
(0.13 mg/ml). Catheter patency checks were conducted
once aweek onweekends using a 1 mg/0.1 ml i.v. push of
methohexital sodium (Henry Schein, Indianapolis, IN,
USA), which produces a 10–20-second loss of conscious-
ness with patent catheters. Rats with failed or infected
catheters were excluded from the experiment.
In preparation for nicotine self-administration on
PD-59, to promote exploratory behavior, food restriction
was started, maintaining body weight at 85% of pre-
restriction weight (with 2–3 bricks/day of standard rat
chow). This restriction continued for all rats until the fifth
acquisition session. Self-administration sessions began on
PD-60 in Med Associates chambers controlled by soft-
ware that recorded instrumental activity. These units,
housed inside sound-attenuating cubicles, were equipped
with two non-retractable levers with cue lights, a house
light and an infusion pump assembly (Razel Model A
pump; Med Associates).
All self-administration sessions were 2 hours long
beginningwith house light on to signal nicotine availabil-
ity anda single priming infusion of nicotine. Responses on
the active lever (counterbalanced left/right between
animals) resulted in house lights off and drug-paired
lever cue light on for a 3-second infusion (0.015 mg/kg
nicotine in 0.050 ml saline; FR1 schedule). A 17-second
time-out followed with all lights out during which
recorded lever presses produced no consequences. Rats
progressed through three stages of sessions: acquisition,
dose-response testing and extinction, with no days off
between stages. For acquisition, rats were given a
maximum of 35 once daily sessions, during which they
were regarded as having acquired self-administration
when they had accumulated (not necessarily consecu-
tively) 20 days of > 20 active lever presses (nicotine hits)
per day (i.e. resulting in a minimum exposure of 6 mg/kg
nicotine during acquisition). These sessions occurred
on a Monday–Friday (5 day) schedule with weekends
(2 days) off so that rats remained in acquisition from4 to7
weeks depending on performance. Through acquisition,
any rat that did not press once on the active lever in the
prior session had a single sucrose pellet placed on the
active lever for the subsequent session. At the end of
acquisition upon reaching the 20 days/20 hits criteria or
the 35th session, whichever came first, rats progressed on
the very next day to the dose-response stage duringwhich
they had access to 7.5, 15, 30 and 15 μg nicotine/kg/
infusion (one dose per session; not counter-balanced) over
four daily sessions. The day after their last dose-response
day, rats began once daily extinction sessions (2 hours; no
nicotine pre-injections; house lights only on; lever presses
producing no consequences), proceeding through these
sessions until responding with ≤ 5 presses on the previ-
ously active lever and ≤ 10 presses on the inactive lever.
Adult radial arm maze (RAM) testing
Rats separate from those undergoing self-administration
were prepared for cognitive testing on the RAM begin-
ning on PD-60, with food restriction (to maintain weight
at 85% of pre-restriction weight) starting on PD-59. Rats
were fed regular chow after daily sessions. The RAM (Med
Associates) was constructed in plexiglass and equipped
with a central octagonal arena (29.5 cm diameter)
with eight runways extending radially (61 × 9 cm with
17 cm high walls), standing 6.5 cm above the floor and
surrounded by consistent visual landmarks.
In spatial learning andworkingmemory testing based
on the win-shift paradigm (Olton & Samuelson 1976),
rats learned in daily sessions to efficiently enter all eight
arms of the maze as reinforced by one-half of a Kellogs®
Froot Loop® loaded at the end of each arm. Sessions
lasted a maximum 300 seconds, or when animals had
entered all eight arms, whichever came first. Three
primary dependent measures were (1) entries-to-repeat
(ETR: the total number of arms entered before the rat
repeated an arm entry; (2) total session time and (3) Froot
Loops consumed. Rats were tested over 24 (once daily)
sessions organized into eight blocks of three sessions,
spanning five sequential phases. In phase 1 (block 1), all
animals received a pre-injection of saline (sc) 30 minutes
prior to the session. In phase 2 (blocks 2–4), NVHL and
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Sham rats were randomized to receive saline or nicotine
injections (0.5 mg/kg sc) 30 minutes prior. In phase 3
(blocks 5 and 6), all animals were only given saline pre-
injections. Subsequently, animals were given a 2-week
break in their home cages, then resumed testing for
phase 4 (block 7) in which they were all given saline
pre-injections followed by phase 5 (block 8) when they
were all given nicotine (0.5 mg/kg) pre-injections.
Histology
After behavioral testing, rats were sacrificed by decapita-
tion under brief isoflurane anesthesia. Brains were
removed whole and cryostat cut into coronal sections
(40 μm) through the rostral-caudal extent of the
hippocampus. Mounted sections were fixed and thionin
(0.5%) stained. Microscopic examination of sections for
lesion verification was performed separate from, and
blind to behavioral data; rats without appropriate lesions
were excluded from the study. Appropriate lesions were
identified as those showing bilateral evidence of tissue
atrophy, paucity of nuclei and cellular disarray (with
lateral ventricular enlargement) confined to the ventral
hippocampus (Fig. 1). Brains with unilateral damage,
damage encompassing the dorsal blades of the hippo-
campus, or direct damage to nearby structures (temporal
cortex, amygdala, thalamus, basal ganglia) were
excluded. From the self-administration experiment, 23 of
33 rats (70%) that underwent ibotenic acid delivery and
had successful catheters, had appropriate hippocampal
malformations and were included in the study. From the
RAM experiment, 17 of 25 (68%) of ibotenic-exposed
rats had acceptable NVHLs.
Data analysis
Parametric testing examined dependent variables of
locomotor activity (cm/hour) in behavioral sensitization.
Active and inactive lever pressing, nicotine intake and
time-out pressing (on active and inactive levers) were
examined in self-administration. ETR, session time and
Froot Loops consumed, taken as the mean of three
consecutive sessions for each blockwere dependentmeas-
ures in RAM testing. Two-way analysis of variance
(ANOVA) with independent variables lesion status and
nicotine history was used with repeated measures testing
across multiple sessions as appropriate. In sensitization/
self-administration, the nicotine variable referred to ado-
lescent nicotine versus saline exposure. In RAM testing,
the nicotine variable reflected nicotine versus saline pre-
injections during maze learning. Separate ANOVAs were
applied to different phases of self-administration and
RAM experiments. Significancewas identified at P < 0.05
with mention of notable negative or marginal effects.
Wherever significant interactions occurred between
main effects and repeated time measures, secondary one-
wayANOVAswere applied to specifywhen in the repeated
measure the main effect was strongest.
RESULTS
Adolescent nicotine sensitization and adult
self-administration
In the first experiment, 45 rats first underwent daily
experimenter-delivered injections of nicotine (0.5 mg/kg
sc) (NVHL, n = 12; Sham, n = 10) or saline (1 ml/kg sc)
(NVHL, n = 11; Sham, n = 12) for 10 days during
mid-adolescence (PD 35–44) followed by adult self-
administration (PD-60). This early nicotine exposure
tested whether abnormal nicotine responsiveness occurs
in NVHLs prior to the periadolescent onset of the full
syndrome, and whether it interacts with NVHLs to
alter adult self-administration. Although adolescent
nicotine injections robustly sensitized locomotor activity
Figure 1 Mapping of hippocampal
damage in neonatal ventral hippocampal
lesions (NVHL) rats. (a) Coronal maps
[from bregma (mm)] show the rostral-
caudal extent of largest (black) to smallest
(white inset) hippocampal damage among
the 82 rats in the study. (b) Photomicro-
graphs show typical NVHL histology versus
a SHAM-operated control brain. [Maps are
adapted from Swanson LW (2004) Brain
Maps: Structure of the Rat Brain, 3rd edn.
New York: Elsevier.]
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(day × nicotine: F9,369 = 39.8, P < 0.001; nicotine: F1,41 =
261.5,P < 0.001), adolescent NVHL rats did not sensitize
differently from Shams (Fig. 2).
Upon reaching adulthood (PD-56), these 45 rats
underwent jugular venous catheterization followed by i.v.
nicotine self-administration 4 days later. Only the first 20
days of acquisition were analyzed (Fig. 3a–d) since over
acquisition days 21–35, treatment group’s numbers
began to drop differentially as ratsmet acquisition criteria
(20 days > 20 nicotine infusions/day) and progressed to
dose-response testing. Over the first 20 days, nicotine was
generally self-administered in increasing amounts via
active lever presses (i.e. presses that delivered infusions)
(days: F19,779 = 14.6, P < 0.001) (Fig. 3a), with no
growth in inactive lever pressing (Fig. 3b). NVHL rats
showed stronger acquisition in terms of active lever
pressing (lesion: F1,41 = 16.0, P < 0.001) and shape of
the acquisition curve (lesion × days: F19,779 = 2.05, P <
0.01). Post hocANOVAs (one way by lesion status on each
day) detected significant increases in NVHL responding
initially emerging on days 4 and 5, then becoming larger
and more frequent over the next 3 weeks of acquisition.
NVHLs did not differ from Shams on inactive lever press-
ing but they did show increased active lever time-out
responding (lesion: F1,41 = 9.1, P < 0.01) (Fig. 3c). Time-
out responding at the inactive level was flat and not
different between groups (Fig. 3d).
Based on the acquisition criteria in which all rats were
given up to 35 days to achieve 20 days of ≥ 20 nicotine
infusions/day, NVHL rats achieved acquisition criteria in
fewer days than Shams (lesion: F1,41 = 7.3, P < 0.01)
(Fig. 3e) and therefore entered the dose-response testing
earlier. This provided the Shams with the opportunity of
more acquisition sessions to catch up to the NVHLs in
terms of cumulative nicotine intake. Even with this
experimental design, NVHLs still had a greater total
nicotine intake (lesion: F1,41 = 9.0, P < 0.01) (Fig. 3f) as
calculated over all acquisition sessions.
Adolescent nicotine exposure had no effects or inter-
actions on any measure during the acquisition stage of
nicotine self-administration. However, during dose-
response testing analyzed over 5 days, in which the last
acquisition session was considered the first dose-response
session, a dose-dependent effect of adolescent nicotine
history on nicotine intake did emerge without lesion
effects (day × nicotine history: F4,164 = 3.4, P < 0.05)
(Fig. 4a). One-way (by nicotine history) post hoc ANOVAs
performed across dosing days detected a nicotine-history-
associated increase in nicotine intake at the 30 μg dose
(F1,44 = 4.1, P < 0.05). As expected for dose-response
testing, both daily nicotine intake (Fig. 4a) and active
lever presses (Fig. 4b) varied significantly across days
[(day: F4,164 = 40.3, P < 0.001) and (day: F4,164 = 10.1,
P < 0.001), respectively]. However, inactive lever press-
ing did not differ across days or by lesion status or nicotine
history. In parallel to active lever pressing, time-out active
lever pressing did vary significantly across days (day:
F4,164 = 9.2, P < 0.001) (Fig. 4d), also without lesion or
nicotine history effects. Time-out inactive lever pressing
(Fig. 4e) also varied across days (day: F4,164 = 3.1,
P < 0.05) with a day × lesion interaction (F4,164 = 2.5,
P < 0.05), in which Shams pressed more on the middle
day (15 μg dose) (F1,44 = 5.7, P < 0.05). Despite this sta-
tistical significance, these effects in time-out inactive lever
pressing were likely not meaningful due to the extremely
low responding (averaging < 3 hits per 2 hours) observed
over the course of dose-response testing.
Having established that total nicotine intake and
active lever presses did not differ over the five dose-
response sessions according to lesion status, we also
determined more specifically that NVHL and Sham rats
also did not differ on active or inactive lever pressing on
their very last day of nicotine intake (dose-response day
5; 15 μg dose). This confirmed that despite robust lesion-
based differences in active lever responding and nicotine
intake over the acquisition stage, the added acquisition
sessions allotted to Sham rats did allow NVHL and Sham
rats to arrive at comparable levels of nicotine reinforce-
ment and exposure by the time of (and measured over)
the dose-response days just before extinction testing.
Thus, lesion-based differences in subsequent extinction
responding can be interpreted as signifying persistent
changes in nicotine-seeking behavior due to NVHLs,
independent from possible effects of very recent drug-
taking behavior, although lesion-based differences in
nicotine intake earlier in acquisition might be still be
Figure 2 Adolescent nicotine behavioral sensitization is demon-
strated as growth in post-injection locomotion due to nicotine
injections (***P < 0.001) over 10 days.Neonatal ventral hippocampal
lesions (NVHL) rats [nicotine (NIC) (n = 12); saline (SAL) (n = 11)]
did not differ from SHAMS [nicotine (n = 10); saline (n = 12)]. Data
depicted as means ± SEM
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Figure 3 Adult acquisition of nicotine self-administration, same subjects (n = 45) as in Fig. 2. (a) Over the first 20 days, nicotine was
self-administered in increasing amounts via active lever presses (***days: P < 0.001), (b) unaccompanied by growth in inactive lever pressing.
Neonatal ventral hippocampal lesions (NVHL) rats showed stronger acquisition (in terms of overall active lever pressing (***lesion: P < 0.001)
and shape of the acquisition curve (**lesion × days: P < 0.01), while not differing from SHAMS on inactive lever pressing. Significance levels of
post hoc one-way ANOVAs on each day by lesion status are denoted directly above error bars (*P < 0.05; **P < 0.01; ***P < 0.001). (c) NVHLs
increased active lever time-out responding (**P < 0.01) but not (d) time out-inactive lever pressing. Over acquisition, (e) NVHL rats achieved
nicotine acquisition (20 days of ≥ 20 infusions/day) earlier than SHAMS (**P < 0.01), accumulating (f) greater total nicotine intake (**P < 0.01).
Adolescent nicotine exposure (NIC groups) did not produce differential effects on these measures compared to adolescent saline exposure.
Data depicted as means ± SEM
Figure 4 Dose-response testing after
acquisition of nicotine self-administration,
same subjects (n = 45) as in Figs 2 and 3.
(a) Total nicotine intake varied significantly
between days as the doses of nicotine infu-
sions changed (***day: P < 0.001), interact-
ing with nicotine history in adolescence
(*day × nicotine hx: P < 0.05).This effect was
carried by nicotine history-related increases
in intake at the highest nicotine dose (one-
way ANOVA by nicotine history: *P < 0.05).
(b) Active lever presses differed across days
(***P < 0.001). (c) Inactive lever pressing
did not vary significantly whereas (d) Time-
out active lever responding did vary by day
(***P < 0.001) as did (e) time-out inac-
tive lever pressing (P < 0.05) where sham
rats showed greater responding in a dose
dependent manner (*day × lesion: P < 0.05)
with shams showing greater responding
specifically at the middle 15 μg dose (post
hoc ANOVA by nicotine history: *P < 0.05).
Data are depicted as means ± SEM
throughout all figures
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predictive of, or contribute to, later extinction differences.
Indeed, in the first extinction session when rats pursued
nicotine in daily 2-hour sessions, but without nicotine
reinforcement, NVHL rats again demonstrated greater
active lever responses (lesion: F1,41 = 7.5, P < 0.01)
(Fig. 5a). When dividing the first extinction session into
4 × 30-minute segments, this main effect was accompa-
nied by a significant within-session tapering of active
lever pressing from an initial extinction burst (segment:
F3,123 = 94, P < 0.001). Compared to their overall average
of 8.1 presses per 30minutes recorded in their final dose-
response session when they were receiving nicotine,
active lever pressing was higher for all rat groups in the
first 30 minutes of the first extinction session, dropping
below the 8.1 average across the 30- to 120- minute
segments. A lesion × segment interaction (F3,123 = 8.2,
P < 0.001) indicated that NVHLs amplified the magni-
tude of the extinction burst as confirmed by a post hoc
one-way (lesion status) ANOVA testing at each time
segment, which showed a significant increase for NVHLs
in the first 30-minute segment (F1,44 = 8.2,P < 0.001). In
analysis of extinction responding over a longer time span
encompassing the first 3 days of extinction testing, NVHL
rats also showed persistent elevations in drug seeking on
the previously nicotine-paired lever (lesion: F1,36 = 8.6,
P < 0.01), superimposed on an extinguishing pattern of
responding across days (day: F2,72 = 30.2, P < 0.001)
(Fig. 5b). On the inactive lever, where respondingwas still
much less overall than at the previously nicotine-paired
lever, an overall extinction pattern was also observed
(day: F2,72 = 8.7, P < 0.001) with Sham rats tending to
have higher responding than NVHLs on day 1 that
habituated significantly more compared to NVHLs over
the 3 days (day × lesion: F2,72 = 5.5, P < 0.01) (Fig. 5c).
Adult learning and working memory deficits and
response to nicotine
Different sets of NVHL and Sham rats (n = 37) entered a
second experiment beginning in adulthood (PD- 60) that
tested the effects of nicotine on learning and working
memory performance on the eight-armRAM.This testing
measures prefrontal-cortical-hippocampal network dys-
function analogous to that underlying the contextual-
spatial working memory deficits in human schizophrenia
(Fuller et al. 2009; Gold et al. 2010) and is sensitive to
nicotinic receptor manipulation and the NVHL model
(Levin 1988; Chambers et al. 1996). All rats received
saline pre-injections 30 minutes before testing across
blocks 1, 5, 6 and 7 but were randomized to receive nine
(oncedaily)nicotinepre-injections (0.5 mg/kg sc) (NVHL,
n = 9; Sham, N = 10) or saline (NVHL, n = 8; Sham,
n = 10) before testing across blocks 2–4. By design, this
dosing regimen closely approximated that used in the first
experiment. In nicotine sensitization, the 10 × 0.5 mg/kg
doses (5 mg/kg total exposure) were behaviorally activat-
ing (compared to saline) from 10 to 60 minutes post-
injection. In nicotine self-administration, the acquisition
criteria of a minimum of 20 infusions/day × 20 days
would producea total exposure of approximately6 mg/kg
within 20 to 35 sessions.
Over the first block of RAM testing, NVHL rats showed
no impairments in entries-to-repeat (ETR) (Fig. 6a)
but were significantly slower in session time (lesion:
F1,33 = 2.1, P < 0.05) (Fig. 6b) while showing no differ-
ences in Froot Loops eaten (Fig. 6c). Across blocks 2–4,
all rats demonstrated learning with increased ETRs
(blocks: F2,66 = 13.6, P < 0.001), decreased session times
(blocks: F2,66 = 63.5, P < 0.001) and more Froot Loops
Figure 5 Drug seeking measured by extinction phase lever pressing. For extinction day 1, same subjects (n = 45) are included as in Figs 2–4.
Subsequent extinction day analyses exclude rats that had met extinction criteria on previous days [day 2: n = 2 sham; n = 1 neonatal ventral
hippocampal lesions (NVHL);day 3:n = 3 sham;n = 2NVHL] (a) During extinction day 1,divided into 4 × 30-minute segments,an extinction burst
marked by increased rates of active lever pressing in the first 30 minutes [compared to the 8.1 active lever presses per 30 minutes recorded in
the prior nicotine reinforced session (horizontal line)] extinguished significantly over the next 90 minutes (***segment:P < 0.001).Overall lesion
effects (**lesion: P < 0.01 and ***segment × lesion: P < 0.001) to increase drug seeking were carried most prominently by increased pressing
during the initial extinction burst (one-way by lesion status: P < 0.001). (b) Over the first three extinction days on the previously nicotine-paired
lever, NVHLs again showed elevated drug seeking (**P < 0.01) superimposed on an extinguishing pattern (***day; P < 0.001), while on the
inactive lever (c), SHAM rats tended to have higher responding that habituated more significantly (**day × lesion: P < 0.01; ***day: P < 0.001).
Unlike the dose-response data, adolescent nicotine history effects had no effects on nicotine seeking during extinction
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Figure 6 Radial arm maze testing of spatial learning and working memory. Rats received nine once daily nicotine (neonatal ventral
hippocampal lesions; (NVHL, n = 9; SHAM, n = 10) versus saline pre-injections (NVHL, n = 8; SHAM, n = 10) across blocks 2–4 with all receiving
saline elsewhere except for the last block where they all received nicotine. In block 1, NVHL rats showed no impairments in (a)
entries-to-repeat (ETR) but were (b) significantly slower in session time (*P < 0.05). Across blocks 2–4, rats demonstrated learning with
increased ETRs (***P < 0.001), decreased session times (***P < 0.001), and more (c) Froot Loops eaten (***P < 0.001), but NVHL rats
showed impaired cognition with lower ETRs (***P < 0.001). Nicotine pre-injections produced no effects on ETR where the cognitive deficits
due to NVHLs were most robust, but did improve cognitive efficiency in terms of reduced session time (*P < 0.05).This improvement did not
specifically reverse NVHL deficits on session time (*lesion: P < 0.05). Over blocks 5–6, the recent nicotine exposure produced new cognitive
deficits in terms of session time (*P < 0.05) with NVHL deficits in ETR (*** P < 0.001) and session time persisting (**P < 0.01). In long-term
recall ending with nicotine pre-injections (block 7–8),NVHL deficits in ETR (block #7; **P < 0.01; block #8:** P < 0.01) and session time (block
#7:* P < 0.05; block #8: **P < 0.01) also persisted, with no group differences in Fruit Loops consumed and no effects or interactions with prior
nicotine pre-injections (blocks 2–4)
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eaten (blocks: F2,66 = 38.5, P < 0.001). Now, NVHL rats
did show impaired cognition with lower ETRs (lesion:
F1,33 = 26.7, P < 0.001) that could not be due to differ-
ences in food reward motivation since there were no
lesion-based differences in Froot Loops consumed. Effi-
ciency in completing themazewas also again impaired by
NVHLs (lesion: F1,33 = 4.6, P < 0.05), but enhanced by
nicotine pre-injections (nicotine: F1,33 = 5.5, P < 0.05).
Nicotine pre-injections did not improve ETR however,
and did not interact with NVHLs to specifically reverse
NVHL deficits in ETR or session time.
Over blocks 5 and 6, when all rats were again receiv-
ing saline pre-injections, the recent nicotine exposure
produced new cognitive deficits in terms of marginally
worsening ETR (nicotine: F1,33 = 3.6, P = 0.06) and sig-
nificantly worsening session time (nicotine: F1,33 = 4.4,
P < 0.05). NVHL deficits in ETR (lesion: F1,33 = 21.8, P <
0.001) and session time (lesion: F1,33 = 14.8, P < 0.01)
persisted across these blocks and were not interactive
with the effects of prior nicotine exposure. Figure 7
depicts the session data covering the transition from
nicotine pre-injections back to saline pre-injections (bins
4 through 6). These groupings plotted according to nico-
tine exposure (Fig. 7a) and lesion status (Fig. 7b) allow a
more clear view of the effects of nicotinewithdrawal (and
NVHLs) on cognition.
After block 6, all animals had 2 weeks off from RAM
testing so that subsequent blocks would serve as meas-
ures of long-term recall. Nicotine pre-injections were
given in the final (eighth) block to all rats to test for poten-
tial ‘nicotine rescue’ effects of any cognitive deficits.
Across blocks 7 and 8, NVHL deficits in ETR (lesion:
block #7: F1,33 = 12.2, P < 0.01; block #8: F1,33 = 10.6,
P < 0.01) (Fig. 6a) and session time (lesion: block #7:
F1,33 = 7.0, P < 0.05; block #8: F1,33 = 11.7, P < 0.01)
(Fig. 6b) persisted, with no group differences in Froot
Loops consumed (Fig. 6c) and no effects of prior nicotine
(or nicotine history interactions with NVHLs) on any
measures.
DISCUSSION
This study demonstrates that early developmental
hippocampal damage increases the reinforcing effects of
nicotine in adulthood while also producing cognitive
impairments that are not specifically treated by nicotine.
This modeling accurately simulates clinical phenome-
nology of greater severities of nicotine dependence in
mentally ill people, including observations of schizophre-
nia patients consuming more nicotine than non-
schizophrenic, nicotine-dependent subjects (Williams
et al. 2005). While contributing to mounting evidence
pointing to the importance of hippocampal function in
the pathogenesis of addictive disorders (Chambers et al.
2001; Sudai et al. 2011; Chambers 2013), these findings
replicate, and begin to biologically explain, enhanced
nicotine addiction vulnerability in the absence of specific
cognitive therapeutic effects of nicotine in schizophrenia
subjects (Hahn 2013).
NVHLs impact the maturation and function of
prefrontal cortical-ventral striatal circuits to which the
ventral hippocampus directly projects, in multiple ways
that correspond to neural and behavioral findings in
human schizophrenia and subjects with addictions (Liu
et al. 1998; Chambers et al. 2001; Heerey, Bell-Warren &
Gold 2008; Tseng et al. 2009). Behaviorally, NVHL rats
show baseline cognitive impulsivity in their approach to
natural rewards that is worsened by prior cocaine history
(Chambers et al. 2005), mirroring impulsivity found in
populations with nicotine dependence and other addic-
tions (Bickel, Odum & Madden 1999). The present study
identified impulsive and perseverative styles of nicotine
seeking in theNVHLmodel like those previously shown in
cocaine self-administration (Chambers & Self 2002).
Figure 7 Radial arm maze session times covering the transition
from nicotine to saline pre-injections, same subjects (n = 37) as in
Fig. 6 with blocks 4, 5 and 6 decomposed into individual sessions for
visual clarity. Comparison of rats according to (a) nicotine versus
saline exposure (during sessions 4–12) depicts the detrimental cog-
nitive effects of nicotine withdrawal. The comparison by (b) lesion
status suggests how nicotine withdrawal impacts NVHL and Sham
rats similarly
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Specifically, NVHL rats showed increased active lever
time-out responding during acquisition of nicotine
self-administration and increased nicotine seeking in
extinction, that mirror the same abnormalities they show
in cocaine self-administration. Together, these findings
confirm that NVHLs produce a failure in inhibitory
control over motivated behavior associated with multiple
addictive drugs abused at particularly high rates in
schizophrenia.
BothNVHLs and human smokers show prefrontal cor-
tical regional atrophy (Chambers et al. 2010a; Durazzo
et al. 2013). In NVHL rats, this prefrontal atrophy corre-
sponds to pyramidal cell neuronal atrophy and derange-
ments in excitatory and inhibitory neurotransmission,
occurring on top of neostriatal supersensitivity to dopa-
mine signaling (Tseng et al. 2007; Chambers et al.
2010a; Chambers, Sentir & Engleman 2010b). Together,
these abnormalities may contribute to enhanced recruit-
ment of striatal activation patterns associated with
addictive drug-induced behavioral adaptation in NVHL
rats (Tseng et al. 2007; Chambers et al. 2010a) result-
ing in augmented behavioral sensitization and self-
administration with multiple addictive drugs (Chambers
& Self 2002; Conroy et al. 2007; Chambers et al. 2010a;
Berg et al. 2011).
Given that the NVHL model increases behavioral
sensitization to nicotine in adulthood (Berg & Chambers
2008) but not in adolescence as shown here, we can
surmise that heightened nicotine responsiveness due to
early hippocampal perturbation is involuntary, and
emerges developmentally in phase with the post-
adolescentonset of the full schizophrenia syndromeof the
model.These findings comportwith emerging clinical and
neuroimaging data suggestive of a developmental coinci-
dence, and neurobiological connection between nicotine
addiction vulnerability and schizophrenic pathology in
the brain, in which altered maturation of prefrontal-
cortical striatal circuits plays a major role (Chambers,
Taylor&Potenza2003;Compton et al. 2009;Zhang,Stein
& Hong 2010). Abnormalities in cortical-hippocampal
network architecture and function, due to a large variety
of genetic and early environmental backgrounds are
implicated across mental illnesses other than schizophre-
nia—including post-traumatic stress disorder, borderline
personality and primary mood disorders (Bremner et al.
2000; Teicher, Anderson & Polcari 2012)—which also
encompass elevated rates of nicotine addiction (Lasser
et al. 2000; Grant et al. 2004; Pulay et al. 2010). Accord-
ingly, the present findings may also illustrate a more
general role of hippocampal malfunction in generating
addiction vulnerability leading to many ‘dual diagnosis’
combinations that involve nicotine.
Adolescent nicotine exposure in rats similar to
what we employed can produce adult prefrontal cortical
physiological abnormalities with cognitive deficits that
resemble those characterized in schizophrenia (Counotte
et al. 2009, 2011). Adolescent nicotine injections also
amplify nicotine sensitization tested in adulthood
(Bracken et al. 2011). Our study design did not test these
effects, and we did not see adolescent nicotine sensiti-
zation impact adult self-administration in the same
way that the NVHLmodel did.The relative lack of effect of
the adolescent nicotine exposure on subsequent adult
nicotine self-administrationmay have been due to several
concurrent factors: The adolescent exposure was not self-
administered, it was not delivered i.v., and it was delivered
in a different context from the adult self-administration.
Further, as hinted by the dose-response testing, where
only the 30 μg dose revealed a significant adolescent
nicotine-history effect, the 15 μg dose we used in acqui-
sition may have been too low to reflect prior nicotine
exposure effects. Finally, it is possible that NVHLs pushed
nicotine reinforcement to a ceiling where relatively
weaker nicotine dose history effects were largely
obscured.
In cognitive testing, adult nicotine exposure produced
mild learning benefits at least in terms of time efficiency
in completing the RAM. However, this beneficial effect
was not specific to NVHL rats, improving Sham perfor-
mance as well. Nicotine also did not at all ameliorate the
primary cognitive deficit measure of ETR that is actually
the most robustly impaired dimension of cognition in
NVHLs measured on the RAM. Finally, the non-specific
mild cognitive benefit of nicotine came at a price in terms
of actually impairing performance once the nicotine
stopped, producing new deficits that resembled a mild
form of what the NVHL model does to cognition even
without nicotine exposure. Again, this nicotine with-
drawal effect occurred non-specifically in NVHL and
Sham rats alike, indicating that the net short-term cost-
benefits of nicotine on cognition in the NVHL are not
different from Shams. These observations are consistent
with rigorously controlled human experimentation dem-
onstrating a lack of differential cognitive benefits of nico-
tine in healthy versus schizophrenia nicotine users, and
detrimental cognitive effects of nicotine withdrawal
(Hahn 2013). Together with emerging animal and
human data suggesting that chronic nicotine exposure
can actually worsen cognition and other psychiatric
symptoms (Reitz et al. 2007; Slotkin 2008; Counotte
et al. 2011; McDermott et al. 2013), our findings suggest
the feasibility of two, non-contradictory, bidirectional
causal dynamics underlying the link between schizophre-
nia and nicotine addiction, in which each disease
worsens the severity of the other. We did not test every
possible manner in which nicotine could work as a medi-
cine for abnormalities in the NVHL model or schizophre-
nia, and therefore cannot rule out the possibility that
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nicotine could still be therapeutic in some way. However,
our results showing that early developmental perturba-
tion of the hippocampus amplifies the reinforcing action
of nicotine, while also producing cognitive problems
that are not specifically or differentially treatable with
nicotine, calls into question the self-medication hypoth-
esis as the most widely espoused explanation for high
rates of nicotine dependence in schizophrenia.
These findings highlight what could be a central
pitfall in the self-medication explanation in that it
focuses on, and promotes, only a therapeutic value to
nicotine, while ignoring its highly addictive activity, and
the likelihood that it is this activity that is pathologically
amplified by the biology of mental illness. In circumvent-
ing this issue, these data provide a new view on neuro-
developmental mechanisms that predispose the mentally
ill to nicotine addiction that should be studied further in
this model and in human subjects for discovery of new
prevention and treatment strategies. Perhaps more
immediately, these findings provide a neuroscientific
demonstration accessible to clinicians and patients alike
that identifies nicotine dependence, not as a medication-
modality for mental illness, but as a co-morbid addic-
tion to which the mentally ill are highly biologically
vulnerable.
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